Cargando…
Comparison of Incidence of Adjacent Segment Pathology between Anterior Lumbar Interbody Fusion and Transforaminal Lumbar Interbody Fusion Treatments for Lumbosacral Junction
This research compared the incidence of adjacent segment pathology (ASP) between anterior interbody lumbar fusion (ALIF) treatment and transforaminal lumbar interbody fusion (TLIF) treatment. Seventy patients were included in this retrospective study: 30 patients received ALIF treatment, and 40 pati...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8708785/ https://www.ncbi.nlm.nih.gov/pubmed/34941644 http://dx.doi.org/10.3390/tomography7040072 |
_version_ | 1784622772677246976 |
---|---|
author | Wu, Po-Kuan Wu, Meng-Huang Shih, Cheng-Min Lin, Yen-Kuang Chen, Kun-Hui Pan, Chien-Chou Huang, Tsung-Jen Lee, Ching-Yu Lee, Cheng-Hung |
author_facet | Wu, Po-Kuan Wu, Meng-Huang Shih, Cheng-Min Lin, Yen-Kuang Chen, Kun-Hui Pan, Chien-Chou Huang, Tsung-Jen Lee, Ching-Yu Lee, Cheng-Hung |
author_sort | Wu, Po-Kuan |
collection | PubMed |
description | This research compared the incidence of adjacent segment pathology (ASP) between anterior interbody lumbar fusion (ALIF) treatment and transforaminal lumbar interbody fusion (TLIF) treatment. Seventy patients were included in this retrospective study: 30 patients received ALIF treatment, and 40 patients received TLIF treatment at a single medical center between 2011 and 2020 with a follow-up of at least 12 months. The outcomes were radiographic adjacent segment pathology (RASP) and clinical adjacent segment pathology (CASP). The mean follow-up period was 42.10 ± 22.61 months in the ALIF group and 56.20 ± 29.91 months in the TLIF group. Following single-level lumbosacral fusion, ALIF is superior to TLIF in maintaining lumbar lordosis, whereas the risk of adjacent instability in the ALIF group is significantly higher. Regarding ASP, the incidence of overall RASP and CASP did not differ significantly between ALIF and TLIF groups. |
format | Online Article Text |
id | pubmed-8708785 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-87087852021-12-25 Comparison of Incidence of Adjacent Segment Pathology between Anterior Lumbar Interbody Fusion and Transforaminal Lumbar Interbody Fusion Treatments for Lumbosacral Junction Wu, Po-Kuan Wu, Meng-Huang Shih, Cheng-Min Lin, Yen-Kuang Chen, Kun-Hui Pan, Chien-Chou Huang, Tsung-Jen Lee, Ching-Yu Lee, Cheng-Hung Tomography Article This research compared the incidence of adjacent segment pathology (ASP) between anterior interbody lumbar fusion (ALIF) treatment and transforaminal lumbar interbody fusion (TLIF) treatment. Seventy patients were included in this retrospective study: 30 patients received ALIF treatment, and 40 patients received TLIF treatment at a single medical center between 2011 and 2020 with a follow-up of at least 12 months. The outcomes were radiographic adjacent segment pathology (RASP) and clinical adjacent segment pathology (CASP). The mean follow-up period was 42.10 ± 22.61 months in the ALIF group and 56.20 ± 29.91 months in the TLIF group. Following single-level lumbosacral fusion, ALIF is superior to TLIF in maintaining lumbar lordosis, whereas the risk of adjacent instability in the ALIF group is significantly higher. Regarding ASP, the incidence of overall RASP and CASP did not differ significantly between ALIF and TLIF groups. MDPI 2021-12-02 /pmc/articles/PMC8708785/ /pubmed/34941644 http://dx.doi.org/10.3390/tomography7040072 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Wu, Po-Kuan Wu, Meng-Huang Shih, Cheng-Min Lin, Yen-Kuang Chen, Kun-Hui Pan, Chien-Chou Huang, Tsung-Jen Lee, Ching-Yu Lee, Cheng-Hung Comparison of Incidence of Adjacent Segment Pathology between Anterior Lumbar Interbody Fusion and Transforaminal Lumbar Interbody Fusion Treatments for Lumbosacral Junction |
title | Comparison of Incidence of Adjacent Segment Pathology between Anterior Lumbar Interbody Fusion and Transforaminal Lumbar Interbody Fusion Treatments for Lumbosacral Junction |
title_full | Comparison of Incidence of Adjacent Segment Pathology between Anterior Lumbar Interbody Fusion and Transforaminal Lumbar Interbody Fusion Treatments for Lumbosacral Junction |
title_fullStr | Comparison of Incidence of Adjacent Segment Pathology between Anterior Lumbar Interbody Fusion and Transforaminal Lumbar Interbody Fusion Treatments for Lumbosacral Junction |
title_full_unstemmed | Comparison of Incidence of Adjacent Segment Pathology between Anterior Lumbar Interbody Fusion and Transforaminal Lumbar Interbody Fusion Treatments for Lumbosacral Junction |
title_short | Comparison of Incidence of Adjacent Segment Pathology between Anterior Lumbar Interbody Fusion and Transforaminal Lumbar Interbody Fusion Treatments for Lumbosacral Junction |
title_sort | comparison of incidence of adjacent segment pathology between anterior lumbar interbody fusion and transforaminal lumbar interbody fusion treatments for lumbosacral junction |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8708785/ https://www.ncbi.nlm.nih.gov/pubmed/34941644 http://dx.doi.org/10.3390/tomography7040072 |
work_keys_str_mv | AT wupokuan comparisonofincidenceofadjacentsegmentpathologybetweenanteriorlumbarinterbodyfusionandtransforaminallumbarinterbodyfusiontreatmentsforlumbosacraljunction AT wumenghuang comparisonofincidenceofadjacentsegmentpathologybetweenanteriorlumbarinterbodyfusionandtransforaminallumbarinterbodyfusiontreatmentsforlumbosacraljunction AT shihchengmin comparisonofincidenceofadjacentsegmentpathologybetweenanteriorlumbarinterbodyfusionandtransforaminallumbarinterbodyfusiontreatmentsforlumbosacraljunction AT linyenkuang comparisonofincidenceofadjacentsegmentpathologybetweenanteriorlumbarinterbodyfusionandtransforaminallumbarinterbodyfusiontreatmentsforlumbosacraljunction AT chenkunhui comparisonofincidenceofadjacentsegmentpathologybetweenanteriorlumbarinterbodyfusionandtransforaminallumbarinterbodyfusiontreatmentsforlumbosacraljunction AT panchienchou comparisonofincidenceofadjacentsegmentpathologybetweenanteriorlumbarinterbodyfusionandtransforaminallumbarinterbodyfusiontreatmentsforlumbosacraljunction AT huangtsungjen comparisonofincidenceofadjacentsegmentpathologybetweenanteriorlumbarinterbodyfusionandtransforaminallumbarinterbodyfusiontreatmentsforlumbosacraljunction AT leechingyu comparisonofincidenceofadjacentsegmentpathologybetweenanteriorlumbarinterbodyfusionandtransforaminallumbarinterbodyfusiontreatmentsforlumbosacraljunction AT leechenghung comparisonofincidenceofadjacentsegmentpathologybetweenanteriorlumbarinterbodyfusionandtransforaminallumbarinterbodyfusiontreatmentsforlumbosacraljunction |